AVLNAvalyn Pharma Inc.
Is it safe?
Mostly sound, with a caveat: comfortable debt (AA), but big price swings.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -36% · now 35% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AVLN take a bad year?
Avalyn Pharma Inc. holds $338M more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Debt / equity
- 0.04×
Debt / equity
- Annualised volatility
- 64%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $15M
- Cash and short-term investments
- $352M
- Net cash
- $338M
- Debt / equity
- 0.04×
- Annualised volatilitytwo years of daily moves
- 64%
- Worst drawdown on file
- −36%
- Below its 52-week high
- 35%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry